Alexion AstraZeneca Rare Disease has completed its acquisition of LogicBio Therapeutics, Inc., a pioneering genomic medicine company, for $2.07 per share.
 
The acquisition creates an opportunity to accelerate Alexion’s growth in genomic medicines through unique technology, an experienced rare disease R&D team, and expertise in preclinical development. Frederic Chereau, CEO of LogicBio, will join Alexion as Senior Vice President, Strategy and Business Development.
 
LogicBio becomes a wholly owned subsidiary of Alexion. Alexion will retain LogicBio employees at their current location in Lexington, MA.